Correlation Between Cytokinetics and Monte Rosa

Can any of the company-specific risk be diversified away by investing in both Cytokinetics and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cytokinetics and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cytokinetics and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Cytokinetics and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cytokinetics with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cytokinetics and Monte Rosa.

Diversification Opportunities for Cytokinetics and Monte Rosa

-0.35

Correlation Coefficient

Cytokinetics  Monte Rosa

Very good diversification

The 3 months correlation between Cytokinetics and Monte is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Cytokinetics and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Cytokinetics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cytokinetics are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Cytokinetics i.e., Cytokinetics and Monte Rosa go up and down completely randomly.

Pair Corralation between Cytokinetics and Monte Rosa

Given the investment horizon of 90 days Cytokinetics is expected to under-perform the Monte Rosa. But the stock apears to be less risky and, when comparing its historical volatility, Cytokinetics is 2.3 times less risky than Monte Rosa. The stock trades about -0.22 of its potential returns per unit of risk. The Monte Rosa Therapeutics is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest  1,001  in Monte Rosa Therapeutics on September 12, 2024 and sell it today you would lose (150.00) from holding Monte Rosa Therapeutics or give up 14.99% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cytokinetics  vs.  Monte Rosa Therapeutics

Cytokinetics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cytokinetics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Cytokinetics is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors.

Monte Rosa Therapeutics

Risk-Adjusted Performance

6 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Cytokinetics and Monte Rosa

The main advantage of trading using opposite Cytokinetics and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cytokinetics position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.

The idea behind Cytokinetics and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.